Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Primary-Effusion-Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 10 Mar 2021 Results (n=6) of phase I portion, presented at the 28th Conference on Retroviruses and Opportunistic Infections.